Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRH | P06850 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CRHR1 | P34998 | 10/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 2/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6070464 | 0.85 | CRH (0.59) | CRHCRHR1 | |
| SCHEMBL6070921 | 0.69 | CRHR1 (0.43) | CRHCRHR1 | |
| SCHEMBL6069631 | 0.69 | CRHR1 (0.47) | CRHCRHR1DPP4 | |
| SCHEMBL3151977 | 0.67 | CRHR1 (0.70) | CRHR1 | |
| SCHEMBL6070559 | 0.66 | CRHR1 (0.55) | CRHCRHR1DPP4 | |
| SCHEMBL6496629 | 0.65 | CRHR1 (0.41) | CRHCRHR1DPP4 | |
| SCHEMBL6495917 | 0.64 | NPC1 (0.49) | CRHR1 | |
| SCHEMBL6071090 | 0.63 | CRHR1 (0.42) | CRHCRHR1 | |
| SCHEMBL8149045 | 0.62 | KMT2A (0.36) | KMT2ACRHR1PTGDR2DPP4DPP7 | |
| SCHEMBL5426680 | 0.61 | KMT2A (0.40) | KMT2APTGDR2DPP4DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026317-B2 | Pyrazolotriazines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-04-11 | — | — | US | disclosed |
| US-6960583-B2 | Pyrazolotriazines as CRF antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| US-20040176376-A1 | Pyrazolotriazines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-09-09 | — | — | US | disclosed |
| US-20020147338-A1 | Pyrazolotriazines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147338-A1 | Pyrazolotriazines as CRF antagonists | CRHR1, CRHR2, CRH | CRH 3/4885KMT2A 3039/4885CRHR1 1/4885 |
| US-20040176376-A1 | Pyrazolotriazines as CRF antagonists | CRHR1, CRHR2, CRH | CRH 3/4885KMT2A 3039/4885CRHR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.